St. Renatus, LLC   Report issue

For profit Phase 2 Phase 3
Founded: Fort Collins CO United States (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2008
NCT01302483
First Marketed Drug
2016
tetracaine (pontocaine)
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

ST RENATUS

Active Ingredients

Marketed Drugs (2)

oxymetazoline (ocuclear) (2016)

tetracaine (pontocaine) (2016)

Drugs in Phase 3 Trials (2)

oxymetazoline (ocuclear) (9 trials)

tetracaine (pontocaine) (11 trials)

Drugs in Phase 2 Trials (1)

lidocaine (xylocaine) (1 trial)

Indications

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 3